Alphatec Sees Unusually Large Options Volume (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC) saw some unusual options trading activity on Friday. Traders bought 2,902 call options on the stock. This is an increase of 92% compared to the typical daily volume of 1,511 call options.

Alphatec Stock Up 0.2 %

Shares of ATEC opened at $9.29 on Friday. The stock has a 50 day moving average price of $10.95 and a 200 day moving average price of $8.70. Alphatec has a one year low of $4.88 and a one year high of $14.88. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -7.26 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last released its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Equities research analysts forecast that Alphatec will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Finally, Piper Sandler lifted their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Insiders Place Their Bets

In other Alphatec news, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares in the company, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Patrick Miles sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the sale, the chief executive officer now directly owns 6,152,544 shares in the company, valued at $74,015,104.32. The trade was a 0.81 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 337,321 shares of company stock valued at $3,828,060. Company insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. Lido Advisors LLC lifted its position in Alphatec by 8.4% during the fourth quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after buying an additional 953 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Alphatec by 0.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after acquiring an additional 1,120 shares during the last quarter. Comerica Bank increased its stake in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 1,248 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in shares of Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock worth $100,000 after acquiring an additional 1,342 shares during the period. Finally, Atria Investments Inc boosted its position in shares of Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after acquiring an additional 1,460 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.